Oxidative stress and endothelium dysfunction in diabetes mellitus type 2;Stres oksydacyjny a dysfunkcja śródbłonka w cukrzycy typu 2

Polski Merkuriusz Lekarski

Volumn 25, Issue 146, 2008, Pages 120-123

  Piwowar, A ^a   Knapik Kordecka, M ^a,b   Warwas, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Department and Clinic of Angiology Hypertension and Diabetology ^*

Author keywords

Diabetes mellitus type2; Endothelium; Oxidative stress

Indexed keywords

ACETYLGLUCOSAMINIDASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; BLOOD; HUMAN; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REFERENCE VALUE; VASCULAR ENDOTHELIUM;

ACETYLGLUCOSAMINIDASE; ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MIDDLE AGED; OXIDATIVE STRESS; REFERENCE VALUES;

EID: 51349098794     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bartosz G.: Druga twarz tlenu. PWN, Warszawa, 2004, 226-242.
2. Bonnefont-Rousselot D, Bastard J.P., Jaudon M.C. i wsp.: Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab., 2000, 26, 3, 163-176.
3. Evans J., Goldfine I, Maddux B. i wsp.: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev., 2002, 23, 5, 599-622.
4. Guerci B., Böhme P., Kearney-Schwartz A. i wsp.: Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab., 2001, 27, 436-447.
5. Inoue T., Matsunaga R., Modrooka S. i wsp.: Serum N-acetyl-beta-D- glucosaminidase activity increases in association with insulin resistance in patients with coronary artery disease. Atherosclerosis, 2000, 149, 1, 117-122.
6. Kalousová M., Škrha J., Zima T.: Advanced glycation end products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res., 2002, 51, 6, 597-604.
7. Kalousová M., Zima T., Tesař V. i wsp.: Advanced glycoxidacion end products in chronic diseases - clinical chemistry and genetic background. Mutat. Res., 2005, 579, 1-2, 37-46.
8. Knapik-Kordecka M., Piwowar A., Warwas M.: Zaburzenia równowagi oksydacyjno-antyoksydacyjnej a czynniki ryzyka miażdżycy i powiklania naczyniowe u chorỳch na cukrzycȩ typu 2. Wiad. Lek., 2007, 60, 7-8, 329-334.
9. Ksia̧żek K., Wiśniewski J.: Udział glukozy i reaktywnych form tlenu w powstawaniu naczyniowych powikłań cukrzycy. Przegl. Lek., 2001, 58, 10, 915-918.
10. Kaneto H., Katakami N., Kawamori D. i wsp.: Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid. Redox. Signal., 2007, 9, 3, 355-366.
11. Lee D.H., Ha M.H., Christiani D.C. i wsp.: Gamma-glutamyltransferase and diabetes -a 4 year follow-up study. Diabetologia, 2003, 46, 3, 359-364.
12. Miralles I.M., Coralles I.I, Garcia-Diez L.C. i wsp.: N-acetyl-β-glucosaminidase and α-fucosidase activities in relation to glycosylated hemoglobin levels and retinopathy in diabetes. Clin. Chim. Acta, 1982, 121, 3, 373-378.
13. Ostrowski W., Gumińska M., Krawczyk A.: Ćwiczenia z chemii ogólnej i fizjologicznej. PZWL. Warszawa, 1986, 413-414.
14. Pompella A., Emdin M., Passino C. i wsp.: The significance of serum gamma-glutamyltransferase in cardiovascular disease. Clin. Chem. Lab. Med, 2004: 42, 10, 1085-1091.
15. Selmeci L., Székely M., Soós P. i wsp.: Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic. Res., 2006, 40, 9, 952-958.
16. Singh R., Barden A., Mori T. i wsp.: Advanced glycation end-products: a review. Diabetology, 2001, 44, 2, 129-146.
17. Tatoń J.: Mechanizmy etiopatogenetyczne angiopatii cukrzycowej jako podstawa jej wieloczynnikowego leczenia. Med. Metabol., 2004, 8, 1, 39-50.
18. Skrha J., Hilgertová J.: Relationship of serum N-acetyl-β-glucosaminidase activity to oxidative stress in diabetes melitus. Clin. Chim. Acta., 1999, 282, 1-2, 167-174.
19. Skrha J., Prazny M., Haas T. i wsp.: Comparison of laser-Doppler flowmetry with biochemical indicators of endothelial dysfunction related to early microangiopathy in Type 1 diabetic patients. J. Diabetes Complications, 2001, 15, 5, 234-240.
20. Skvarilova M., Bulava A., Stejskal D. i wsp.: Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech Repub., 2005, 149, 1, 83-87.
21. Stehouwer C.D.: Is measurement of endothelial dysfuncion clinically useful? Eur. J. Clin. Invest., 1999, 29, 6, 459-461.
22. Wiela-Hojeńska A., Orzechowska-Juzwenko K. N-acetylo-beta-D- glukozaminidaza i jej znaczenie kliniczne. Pol. Arch. Med. Wewn, 1999, 10, 4, 359-366.
23. Wierusz-Wysocka B.: Patologia śródbłonka w cukrzycy - możliwości ingereneji terapeutyeznej. Diabetologia Prakt., 2003, 4, 2, 145-152.
24. Witko-Sarsat V., Friedlander M., Nguyen-Khoa T. i wsp.: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int., 1996, 49, 5, 1304-1313.
25. Witko-Sarsat V., Friedlander M., Nguyen-Khoa T. i wsp.: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol., 1998, 161, 5, 2524-2532.
26. Witko-Sarsat V., Gausson V., Nguyen Thu A. i wsp.: AOPP - induced activation of human neutrophil and monocyte oxidative metabolism: A potencial target for N-acetylcysteine treatment in dialysis patients. Kidney Int., 2003, 64, 1, 82-91.